Exhaled nitric oxide and blood eosinophilia: independent markers of preventable risk.

[1]  J. Bird,et al.  Mepolizumab for Severe Eosinophilic Asthma (DREAM): A Multicentre, Double-Blind, Placebo-Controlled Trial , 2013, Pediatrics.

[2]  C. Janson,et al.  Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. , 2013, The Journal of allergy and clinical immunology.

[3]  S. Wenzel,et al.  Dupilumab in persistent asthma with elevated eosinophil levels. , 2013, The New England journal of medicine.

[4]  W. Busse,et al.  Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. , 2013, American journal of respiratory and critical care medicine.

[5]  I. Pavord.  Complex airway disease: an approach to assessment and management. , 2013, The Lancet. Respiratory medicine.

[6]  Christopher E Brightling,et al.  Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. , 2012, American journal of respiratory and critical care medicine.

[7]  J. Maurer.  Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Identification of Biologic Clusters and Their Biomarkers , 2012 .

[8]  Lee， Jk,et al.  Lebrikizumab treatment in adults with asthma. , 2011 .

[9]  P. Gibson,et al.  Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial , 2011, The Lancet.

[10]  Ana Sousa,et al.  Mepolizumab and exacerbations of refractory eosinophilic asthma. , 2009, The New England journal of medicine.

[11]  I. Pavord,et al.  Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial , 2007, European Respiratory Journal.

[12]  I. Pavord,et al.  COPD: an inhaled corticosteroid-resistant, oral corticosteroid-responsive condition , 2006, European Respiratory Journal.

[13]  L. Boulet,et al.  Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations , 2006, European Respiratory Journal.

[14]  J. Cowan,et al.  Exhaled nitric oxide: a predictor of steroid response. , 2005, American journal of respiratory and critical care medicine.

[15]  I. Pavord,et al.  Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial , 2002, The Lancet.

[16]  I. Pavord,et al.  Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids , 2002, Thorax.

[17]  P. Gibson,et al.  Eosinophilic bronchitis: clinical manifestations and implications for treatment , 2002, Thorax.

[18]  F. Hargreave,et al.  Clinical judgement of airway inflammation versus sputum cell counts in patients with asthma. , 2000, The European respiratory journal.

[19]  D. Postma,et al.  Asthma attacks with eosinophilia predict mortality from chronic obstructive pulmonary disease in a general population sample. , 1999, American journal of respiratory and critical care medicine.